Skip to main content

Table 2 HCV RNA response at end of therapy and end of follow up, by therapy.

From: Retreatment of hepatitis C non-responsive to Interferon. A placebo controlled randomized trial of Ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]

HCV RNA negativity – n (%) Group A Interferon and Ribavirin 6 mo (n = 40) Group B Ribavirin 6 mo (n = 40) Group C Placebo 6 mo (n = 37)
end of therapy 14 (35) 1 0 0
end of follow-up 6 (15) 2 0 0
  1. 1p < 0.01 (Pearson Chi-square) 2 p < 0.01 (Pearson Chi-square)